US Patent

US9216179 — Treatment of gout and hyperuricemia

Method of Use · Assigned to Ardea Biociences Inc · Expires 2031-08-01 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of a specific pharmaceutical composition for the treatment of gout and hyperuricemia.

USPTO Abstract

Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.

Drugs covered by this patent

Zurampic (LESINURAD) · Ironwood Pharms Inc
Aloprim (ALLOPURINOL) · Casper Pharma Llc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1806`	—	Zurampic
`U-2104`	—	Aloprim
`U-2104`	—	Aloprim

Patent Metadata

Patent number: US9216179
Jurisdiction: US
Classification: Method of Use
Expires: 2031-08-01
Drug substance claim: No
Drug product claim: No
Assignee: Ardea Biociences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.